首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1319136

全球缺氧治疗市场 - 2023-2030 年

Global Hypoxia Treatment Market - 2023-2030

出版日期: 2023年07月31日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概述

全球缺氧治疗市场规模在 2022 年达到 7760 万美元，预计到 2030 年将达到 1.343 亿美元，2023-2030 年的年复合增长率为 7.2%。缺氧状况的日益普遍、技术的不断进步、临床试验的不断增加、消费者需求的不断增长以及美国食品和药物管理局批准数量的不断增加等因素都可能推动缺氧治疗市场的发展。

缺氧与多种生物过程有关，包括病原微生物感染、癌症、急性和慢性疾病以及许多其他应激反应。低氧诱导因子（HIFs）能感知低氧，从而调节一系列下游基因的表达，这些基因参与了细胞代谢、细胞死亡、细胞增殖、糖酵解、免疫反应、微生物感染和转移等多个过程。

市场动态

缺氧治疗技术的不断进步有望推动全球市场增长

由于各种技术进步，缺氧治疗市场出现了显著增长。许多关键企业通过推出新产品和服务在这些进步中发挥了重要作用。新产品或服务可以提高诊断或医疗设备的生产率和功效。

例如，2023 年 6 月 20 日，Akebia Therapeutics 公司宣布瑞士治疗产品机构批准 Vafseo（伐杜司他）上市，这是一种口服缺氧诱导因子脯氨酰羟化酶（HIF-PH）抑制剂，用于治疗慢性维持性透析成人慢性肾病（CKD）相关症状性贫血。

瑞士医药公司批准 Vafseo 的依据是包括 7500 多名患者在内的开发项目数据，其中包括 vadadustat 用于治疗成年透析患者 CKD 引起的贫血的全球 3 期临床项目。因此，由于上述因素，该市场有望在预测期内得到推动。

美国食品及药物管理局对缺氧病症的批准不断增加，有望推动全球缺氧治疗市场的发展

FDA 批准治疗哮喘、慢性阻塞性肺病和肺炎等缺氧病症的数量不断增加，成为市场增长的主要驱动力。此外，许多关键企业通过推出新产品和服务，在推动市场发展方面发挥了重要作用。

例如，2021 年 8 月 13 日，默克公司宣布一种口服低氧诱导因子-2 α（HIF-2α）抑制剂 WELIREG 获得 FDA 批准，用于治疗患有 Von Hippel-Lindau (VHL)病且需要治疗相关肾细胞癌、中枢神经系统血管母细胞瘤或胰腺神经内分泌肿瘤的成年患者。

此外，2022 年 3 月 15 日，美国食品和药物管理局（FDA）批准了首个 Symbicort 吸入气雾剂仿制药，用于治疗两种常见的肺部疾病，即 6 岁及以上患者的哮喘，以及慢性阻塞性肺病（COPD）（包括慢性支气管炎）患者的气流阻塞维持治疗和减少病情恶化。这种复杂的非专利药物-器械组合产品不用于治疗哮喘急性发作。因此，由于上述因素，市场有望在预测期内得到推动。

对慢性阻塞性肺病等缺氧疾病缺乏认识预计将阻碍全球缺氧治疗市场的增长

据 Dove Press 称，为了解慢性阻塞性肺病在沙特阿拉伯 Aseer 地区的发病率，进行了流行病学研究。该地区居民对慢性阻塞性肺病的认知度很低。只有 34.0% 的人正确了解戒烟对预防慢性阻塞性肺病的重要作用。这项研究表明，迫切需要提高普通人群对慢性阻塞性肺病及其风险因素的认识。应在课程中加强这一主题，并在公共活动和研讨会中进行讨论。此外，还需要在全国范围内开展研究，以帮助政策制定者实施适当的预防和治疗策略，促进人口的肺部健康。

COVID-19 影响分析

COVID-19 大流行对缺氧治疗市场产生了重大影响。大流行期间，许多医疗系统不堪重负，非紧急医疗程序和筛查被推迟或取消。这导致患者缺氧状况的诊断和开始治疗的时间被推迟。因此，一些缺氧症病例在后期才得到诊断，可能会影响治疗效果。

临床试验对于开发新的治疗方法和改善缺氧治疗市场的疗效至关重要。然而，大流行病扰乱了临床试验的进行，许多研究机构暂时停止招生或修改方案，将患者安全放在首位。这导致了试验完成和新疗法上市的延迟。

此外，大流行期间研发工作的重点也发生了转移，主要集中在开发 COVID-19 的疫苗和治疗方法上。资源和注意力的转移可能暂时影响了缺氧相关研发活动的进展。

此外，为了最大限度地降低 COVID-19 传播的风险，医疗服务提供者对治疗方法进行了调整，如减少亲自出诊、增加远程医疗咨询和修改治疗时间表。这些变化影响了患者的整体体验和缺氧治疗市场的管理。

俄乌冲突分析

俄乌冲突对两国生活的各个方面都产生了重大影响，包括医疗保健和缺氧性疾病（如哮喘和慢性阻塞性肺病）的管理。冲突导致受影响地区的医疗基础设施遭到破坏和中断。包括医院和诊所在内的医疗设施可能遭到破坏或无法进入，这使得缺氧性疾病患者难以获得适当的诊断、治疗和后续护理。

冲突可能导致医疗资源供应有限，包括医疗设备、药品和专业医护人员。这种匮乏可能导致缺氧性疾病患者的诊断延误、治疗方案不足和疾病管理不理想。

冲突导致人口流离失所，人们被迫离开家园，到更安全的地区避难。这种流离失所现象可能会扰乱患者接受治疗的连续性，因为他们可能难以获得固定的医疗服务提供者和治疗机构的帮助，从而可能导致慢性疼痛疾病治疗的中断。

此外，冲突及其后果可能会阻碍受影响地区与缺氧性疾病有关的数据收集和研究工作。这可能会影响最新流行病学数据的可用性，阻碍临床试验，并限制对受冲突影响地区缺氧治疗结果的了解。因此，考虑到上述因素，缺氧治疗市场受到俄罗斯和乌克兰冲突的影响不大。

Market Overview

Global Hypoxia Treatment Market reached US$ 77.6 million in 2022 and is expected to reach US$ 134.3 million by 2030 growing with a CAGR of 7.2% during the forecast period 2023-2030. Factors such as the increasing prevalence of hypoxia conditions, continuous advancements in technology, rising clinical trials, increasing consumer demand, and growing FDA approvals are likely to boost the hypoxia treatment market.

Hypoxia is linked to several biological processes which include pathogenic microbe infection, cancers, acute and chronic diseases, and many other stress responses. Hypoxia-inducible factors (HIFs) sense hypoxia to regulate the expressions of a series of downstream genes expression, which participate in multiple processes including cell metabolism, cell death, cell proliferation, glycolysis, immune response, microbe infection, and metastasis.

Market Dynamics

Rising Technological Advancements in Hypoxia Treatment are Expected to Boost the Global Market Growth

The hypoxia treatment market has witnessed significant growth due to various technological advancements. Many key players play a major role in these advancements by launching new products and services. This new product or service can rise the productivity and efficacy of the diagnostic or medical device.

For instance, on June 20, 2023, Akebia Therapeutics, Inc. announced that the Swiss agency for therapeutic products granted marketing authorization for Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.

The Swissmedic approval of Vafseo is based on data from a development program that included over 7,500 patients, including the global Phase 3 clinical program of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Rising FDA Approvals for Hypoxia Conditions are Expected to Boost the Global Hypoxia Treatment Market

The increasing FDA approvals for hypoxia conditions such as asthma, COPD, and pneumonia act as a major driver for the market growth. Also, many key players play a major role in the advancements of the market by launching new products and services.

For instance, on Aug 13, 2021, Merck & Co. announced that WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor received FDA approval for the treatment of adult patients with Von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors.

Additionally, on March 15, 2022, the U.S. Food and Drug Administration (FDA) approved the first generic of Symbicort Inhalation Aerosol for the treatment of two common pulmonary health conditions that is asthma in patients six years of age and older and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis. This complex generic drug-device combination product, are not used to treat acute asthma attacks. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Lack of Awareness Associated with Hypoxia Conditions such as COPD is Expected to Hamper Global Hypoxia Treatment Market Growth

According to Dove Press, epidemiological studies were conducted to access the prevalence of COPD in the Aseer region of Saudi Arabia. The awareness regarding the COPD condition was low among the people of the region. Only 34.0% correctly knew that quitting smoking has an important role in preventing COPD. This study needs an urgent need of improving awareness of COPD and its risk factors in the general population. This subject should be strengthened in the curriculum and discussed in public campaigns and seminars. Furthermore, nationwide study is required to help the policymakers for implementing suitable preventive and curative strategies to promote the pulmonary health of the population.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the hypoxia treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in the diagnosis of hypoxia conditions and initiation of treatment for patients. As a result, some hypoxia disease cases were diagnosed at later stages, potentially affecting treatment outcomes.

Clinical trials are vital for developing new treatments and improving outcomes in the hypoxia treatment market. However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies.

Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of hypoxia related research and development activities.

Also, to minimize the risk of COVID-19 transmission, healthcare providers implemented changes in treatment delivery, such as reducing in-person clinic visits, increasing telemedicine consultations, and modifying treatment schedules. These changes have impacted the overall patient experience and the management of the hypoxia treatment market.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had significant implications for various aspects of life in both countries, including healthcare and the management of hypoxic diseases such as asthma and COPD. The conflict has led to the destruction and disruption of healthcare infrastructure in affected regions. Medical facilities, including hospitals and clinics, may be damaged or inaccessible, making it challenging for patients with hypoxic diseases to receive proper diagnosis, treatment, and follow-up care.

The conflict can result in limited availability of medical resources, including medical devices, medications, and specialized healthcare professionals. This scarcity may lead to delays in diagnosis, inadequate treatment options, and suboptimal disease management for hypoxic disorders patients.

The conflict has resulted in population displacement, with people forced to leave their homes and seek refuge in safer areas. This displacement can disrupt patients' continuity of care, as they may have difficulty accessing their regular healthcare providers and treatment facilities, potentially leading to interruptions in their chronic pain disorder treatment.

Furthermore, the conflict and its aftermath may hinder data collection and research efforts related to hypoxic diseases in the affected regions. This can impact the availability of up-to-date epidemiological data, hinder clinical trials, and limit the understanding of hypoxic treatment outcomes in conflict-affected areas. Therefore, considering the above factors, the hypoxic treatment market has been moderately affected by the conflict between Russia and Ukraine.

Segment Analysis

The global hypoxia treatment market is segmented based on type, disease type, end users, and region.

Owing to Rising Clinical Trials, the Hypoxic Hypoxia Segment Accounted for Approximately 48.6% of the Hypoxia Treatment Market Share

According to ClinicalTrials.gov, on April 25, 2023, Capital Medical University conducted a clinical trial on an exploratory study of intermittent hypoxia treatment in chronic cerebral hypoperfusion. This interventional study aims to investigate the safety and efficacy of intermittent hypoxia treatment in patients with chronic cerebral hypoperfusion. This study is an exploratory study combining intermittent hypoxia treatment with chronic cerebral hypoperfusion, aiming to preliminarily explore the safety and potential effectiveness of intermittent hypoxia treatment in the use of chronic cerebral hypoperfusion. The estimated study completion date is Oct 10, 2023.

Additionally, On Feb 1, 2023, GSK announced that Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) has received the US Food and Drug Administration (FDA), for the once-a-day treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for four months. Jesduvroq is the first innovative medicine for anemia treatment in over 30 years and the only HIF-PHI approved in the US, providing a new oral and convenient option for patients in the US with anemia of CKD on dialysis. Thus, owing to the above factors, the CMOS segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 38.4% of the Market Share in 2022, Owing to the Increasing Research and Development Activities and Well-Established Healthcare Infrastructure

The North American region is anticipated to experience growth in the field of hypoxia treatments due to factors such as rising research and development efforts, a robust healthcare infrastructure, and supportive reimbursement systems. These factors contribute to increased accessibility for patients to access advanced therapies, facilitating the adoption of cutting-edge treatments. This trend is expected to drive the North American region's progress in hypoxia treatment throughout the forecast period.

WELIREG is the first HIF-2α inhibitor therapy approved in the U.S. As an inhibitor of HIF-2α, WELIREG reduces transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis, and tumor growth.

Competitive Landscape

The major global players in the market include: CASI Pharmaceuticals Inc., Aileron Therapeutics, Inc., Lupin Pharmaceuticals, Inc., PharmaShots, Hancock Medical Inc., Hamilton Company, Spotlight Labs, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., and Merck & Co among others.

Why Purchase the Report?

To visualize the global hypoxia treatment market segmentation based on the type, disease type, end users, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of hypoxia treatment market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global hypoxia treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Disease Type
3.3. Snippet by End Users
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising FDA Approvals for Hypoxia Conditions
  - 4.1.1.2. Increasing Clinical Trials for Hypoxia Conditions
- 4.1.2. Restraints
  - 4.1.2.1. Lack of Awareness Associated with Hypoxia Conditions
- 4.1.3. Opportunity
  - 4.1.3.1. Emerging market of Hypoxia treatment
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.1.2. Market Attractiveness Index, By Type
8.2. Hypoxic Hypoxia*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Hypemic Hypoxic
8.4. Histotoxic Hypoxia
8.5. Stagnant Hypoxia

9. By Disease Type

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 9.1.2. Market Attractiveness Index, By Disease Type
9.2. Asthma*
9.3. Chronic Obstructive Pulmonary Disease (COPD)
9.4. Pneumonia
9.5. Others

10. By End Users

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
10.1.2. Market Attractiveness Index, By End Users

10.2. Hospitals
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
- 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.2.6.1. U.S.
  - 11.2.6.2. Canada
  - 11.2.6.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
- 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.3.6.1. Germany
  - 11.3.6.2. U.K.
  - 11.3.6.3. France
  - 11.3.6.4. Italy
  - 11.3.6.5. Spain
  - 11.3.6.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
- 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.4.6.1. Brazil
  - 11.4.6.2. Argentina
  - 11.4.6.3. Rest of South America
11.5. Asia Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
- 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.5.6.1. China
  - 11.5.6.2. India
  - 11.5.6.3. Japan
  - 11.5.6.4. Australia
  - 11.5.6.5. Rest of Asia Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Product Benchmarking
12.3. Company Share Analysis
12.4. Key Developments and Strategies

13. Company Profiles

13.1. CASI Pharmaceuticals Inc.*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Aileron Therapeutics, Inc., LLC.
13.3. Lupin Pharmaceuticals, Inc.
13.4. PharmaShots
13.5. Hancock Medical Inc.
13.6. Hamilton Company
13.7. Spotlight Labs
13.8. GlaxoSmithKline plc
13.9. Sun Pharmaceutical Industries Ltd.
13.10. Merck & Co.

LIST NOT EXHAUSTIVE

14. Appendix

14.1. About Us and Services
14.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

全球缺氧治疗市场 - 2023-2030 年

Global Hypoxia Treatment Market - 2023-2030

市场概述

市场动态

缺氧治疗技术的不断进步有望推动全球市场增长

美国食品及药物管理局对缺氧病症的批准不断增加，有望推动全球缺氧治疗市场的发展

对慢性阻塞性肺病等缺氧疾病缺乏认识预计将阻碍全球缺氧治疗市场的增长

COVID-19 影响分析

俄乌冲突分析

目 录

第 1 章：研究方法与范围

第2章：定义和概述

第 3 章：执行摘要

第四章：动态

第 5 章：行业分析

第 6 章：COVID-19 分析

第 7 章 ：俄乌战争分析

第8章：按类型划分

第 9 章：按疾病类型分类

第10章：按最终用户分类

第 11 章：按地区

第 12 章 ：竞争格局

第 13 章 ：公司简介

第 14 章：附录